Akebia Therapeutics, Inc.
DE ˙ DB ˙ US00972D1054
0,83 € ↓ -0,02 (-2,69%)
2026-06-03
DEL PRIS
SecurityDE:AX9 / Akebia Therapeutics, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership16,106 shares
Latest Disclosed Value $ 22,387
D. E. Shaw & Co., Inc. reports 3.76% increase in ownership of AX9 / Akebia Therapeutics, Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 16,106 shares of Akebia Therapeutics, Inc. (DE:AX9) valued at $18,377 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 15,522 shares of Akebia Therapeutics, Inc.. This represents a change in shares of 3.76% during the quarter. The current value of the position is $13,381 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AKEBIA THREAPEUTICS COM 00972D105 16,106 584 3.76 22 -8.33 0.0000
2026-02-17 2025-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 15,522 -23,604 -60.33 25 -77.36 0.0000
2025-11-14 2025-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 39,126 -179,963 -82.14 107 -86.70 0.0001
2025-08-14 2025-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 219,089 145,928 199.46 797 469.29 0.0006
2025-05-15 2025-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 73,161 -9,500 -11.49 140 -10.83 0.0001
2025-02-14 2024-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 82,661 -300 -0.36 157 44.04 0.0001
2024-11-14 2024-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 82,961 82,961 110 0.0001
2022-08-15 2022-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 0 -22,547 -100.00 0 -100.00
2022-05-16 2022-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 22,547 8,154 56.65 16 -51.52 0.0000
2022-02-14 2021-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 14,393 14,393 33 0.0000
2021-05-17 2021-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -416,583 -100.00 0 -100.00
2021-02-16 2020-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 416,583 -1,613,787 -79.48 1,166 -77.12 0.0010
2020-11-16 2020-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 2,030,370 -291,437 -12.55 5,096 -83.84 0.0052
2020-08-14 2020-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 2,321,807 1,009,842 76.97 31,530 217.04 0.0376
2020-05-15 2020-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 1,311,965 524,334 66.57 9,945 99.78 0.0155
2020-02-14 2019-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 787,631 378,588 92.55 4,978 210.54 0.0057
2019-11-14 2019-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 409,043 -117,549 -22.32 1,603 -37.11 0.0020
2019-08-14 2019-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 526,592 174,805 49.69 2,549 -11.52 0.0032
2019-05-15 2019-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 351,787 -65,391 -15.67 2,881 24.88 0.0037
2019-02-14 2018-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 417,178 312,207 297.42 2,307 148.87 0.0032
2018-11-14 2018-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 104,971 25,396 31.91 927 16.75 0.0011
2018-08-14 2018-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 79,575 47,861 150.91 794 162.91 0.0010
2018-05-15 2018-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 31,714 -19,635 -38.24 302 -60.47 0.0004
2018-02-14 2017-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 51,349 -48,588 -48.62 764 -61.14 0.0011
2017-11-14 2017-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 99,937 79,459 388.02 1,966 568.71 0.0030
2017-08-14 2017-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 20,478 20,478 294 0.0005
2017-05-15 2017-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -14,477 -100.00 0 -100.00
2017-02-14 2016-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 14,477 -8,882 -38.02 151 -28.44 0.0003
2016-11-14 2016-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 23,359 -1,126 -4.60 211 15.30 0.0004
2016-08-15 2016-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 24,485 -3,215 -11.61 183 -26.80 0.0003
2016-05-16 2016-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 27,700 27,700 0.00 250 0.0004
2015-11-16 2015-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 0 0 0 0.0000
2015-05-15 2015-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -14,584 -100.00 0 -100.00
2015-02-17 2014-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 14,584 14,584 170 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.